Home Healthcare  Summary Novavax receives a Hold rating, reflecting neutral fundamentals despite a Q1 earnings beat and strong recent price momentum. NVAX's upside hinges on executing strategic partnerships, notably with Pfizer, and advancing its vaccine pipeline amid sector tailwinds from infectious disease outbreaks. Profitability remains elusive, with negative equity and choppy cash flow; consensus expects no positive EPS until at least 2028. Valuation implies nearly 40% upside to Wall Street's $14.11 target, but technicals and seasonal demand volatility temper conviction in a sustained rally.…